3-(2-hydroxyethyl)-1-[4-[4-[(3S)-3-methylmorpholin-4-yl]-6-(2-methylsulfonylpropan-2-yl)pyrimidin-2-yl]phenyl]thiourea | 1099703-53-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(2-hydroxyethyl)-1-[4-[4-[(3S)-3-methylmorpholin-4-yl]-6-(2-methylsulfonylpropan-2-yl)pyrimidin-2-yl]phenyl]thiourea
• 英文别名: 1-(2-hydroxyethyl)-3-[4-[4-[(3S)-3-methylmorpholin-4-yl]-6-(2-methylsulfonylpropan-2-yl)pyrimidin-2-yl]phenyl]thiourea
• CAS: 1099703-53-3
• 化学式: C₂₂H₃₁N₅O₄S₂
• 分子量: 493.651
• InChiKey: IKTUOUAOGSCKIL-HNNXBMFYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  33
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  157
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  4-[4-[(3S)-3-methylmorpholin-4-yl]-6-(2-methylsulfonylpropan-2-yl)pyrimidin-2-yl]aniline 在 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 4.0h， 生成 3-(2-hydroxyethyl)-1-[4-[4-[(3S)-3-methylmorpholin-4-yl]-6-(2-methylsulfonylpropan-2-yl)pyrimidin-2-yl]phenyl]thiourea
  参考文献：
  名称：

  Discovery of AZD3147: A Potent, Selective Dual Inhibitor of mTORC1 and mTORC2

  摘要：

  High throughput screening followed by a lead generation campaign uncovered a novel series of urea containing morpholinopyrimidine compounds which act as potent and selective dual inhibitors of mTORC1 and mTORC2. We describe the continued compound optimization campaign for this series, in particular focused on identifying compounds with improved cellular potency, improved aqueous solubility, and good stability in human hepatocyte incubations. Knowledge from empirical SAR investigations was combined with an understanding of the molecular interactions in the crystal lattice to improve both cellular potency and solubility, and the composite parameters of LLE and pIC(50)-pSolubility were used to assess compound quality and progress. Predictive models were employed to efficiently mine the attractive chemical space identified resulting in the discovery of 42 (AZD3147), an extremely potent and selective dual inhibitor of mTORC1 and mTORC2 with physicochemical and pharmacokinetic properties suitable for development as a potential clinical candidate.

  DOI：

  10.1021/jm501778s

文献信息

• [EN] MORPHOLINO PYRIMIDINE DERIVATIVES USED IN DISEASES LINKED TO MTOR KINASE AND/OR PI3K<br/>[FR] DÉRIVÉS DE MORPHOLINO PYRIMIDINE UTILISÉS DANS DES MALADIES LIÉES À UNE KINASE MTOR ET/OU À PI3K
  申请人：ASTRAZENECA AB

  公开号：WO2009007750A1

  公开（公告）日：2009-01-15

  A compound of formula (I) or a pharamaceutically acceptable salt thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, for example in the treatment of proliferative disease such as cancer and particularly in disease mediated by an mTOR kinase and/or one or more PI3K enzyme.

  化合物式(I)或其药学上可接受的盐，其制备方法，含有它们的药物组合物以及它们在治疗中的应用，例如在治疗增殖性疾病，如癌症，特别是由mTOR激酶和/或一个或多个PI3K酶介导的疾病中的使用。
• Isoxazoline-substituted benzamide compound and pesticide
  申请人：Mita Takeshi

  公开号：US20070066617A1

  公开（公告）日：2007-03-22

  An isoxazoline-substituted benzamide compound of formula (1) or a salt thereof: wherein A 1 , A 2 and A 3 independently of one another are carbon atom or nitrogen atom, G is benzene ring, etc., X is halogen atom, C 1 -C 6 haloalkyl, etc., Y is halogen atm, C 1 -C 6 alkyl, etc., R 1 is C 1 -C 12 alkyl arbitrarily substituted with R 16 , C 3 -C 2 alkenyl, arbitrarily substituted with R 16 is oxygen atom or sulfur atom, —N(R 20 )R 19 , etc., R 2 is hydrogen atom, C 1 -C 4 alkoxy C 1 -C 6 alkyl, etc., R 3 is C 1 -C 6 haloalkyl, etc., R 16 is halogen atom, cyano, phenyl substituted with (Z) p1 , D-1 to D-60, E-1 to E-49, etc., R 19 is phenyl, phenyl substituted with (Z) p1 , etc., R 20 is hydrogen atom, C 1 -C 6 alkyl, etc., Z is halogen atom, nitro, C 1 -C 4 alkoxy, etc., D-1 to D-60 are 5- or 6-membered aromatic heterocyclic rings, E-1 to E-49 are 5- or 6-membered saturated heterocyclic rings, m is an integer of 0 to 5, n is an integer of 0 to 4, p1 is an integer of 1 to 5. The pesticide containing these compounds.

  一种公式（1）所示的异噁唑基取代的苯甲酰胺化合物或其盐： 其中A1，A2和A3独立地为碳原子或氮原子，G为苯环等，X为卤素原子，C1-C6卤代烷基等，Y为卤素原子，C1-C6烷基等，R1是任意取代的C1-C12烷基，或者任意取代的C3-C2烯基，取代基为R16，R16是卤素原子，氰基，苯基取代的（Z）p1，D-1至D-60，E-1至E-49等，R2为氢原子，C1-C4烷氧基C1-C6烷基等，R3为C1-C6卤代烷基等，R19为苯基，苯基取代的（Z）p1等，R20为氢原子，C1-C6烷基等，Z为卤素原子，硝基，C1-C4烷氧基等，D-1至D-60为5-或6-成员芳香杂环环，E-1至E-49为5-或6-成员饱和杂环，m为0至5的整数，n为0至4的整数，p1为1至5的整数。包含这些化合物的杀虫剂。
• ISOXAZOLINE-SUBSTITUTED BENZAMIDE COMPOUND AND PESTICIDE
  申请人：Mita Takeshi

  公开号：US20090312330A1

  公开（公告）日：2009-12-17

  An isoxazoline-substituted benzamide compound of formula (1) or a salt thereof: wherein A 1 , A 2 and A 3 independently of one another are carbon atom or nitrogen atom, G is benzene ring, etc., X is halogen atom, C 1 -C 6 haloalkyl, etc., Y is halogen atm, C 1 -C 6 alkyl, etc., R 1 is C 1 -C 12 alkyl arbitrarily substituted with R 16 , C 3 -C 12 alkenyl, arbitrarily substituted with R 16 is oxygen atom or sulfur atom, —N(R 20 )R 19 , etc., R 2 is hydrogen atom, C 1 -C 4 alkoxy C 1 -C 6 alkyl, etc., R 3 is C 1 -C 6 haloalkyl, etc., R 16 is halogen atom, cyano, phenyl substituted with (Z) p1 , D-1 to D-60, E-1 to E-49, etc., R 19 is phenyl, phenyl substituted with (Z) p1 , etc., R 20 is hydrogen atom, C 1 -C 6 alkyl, etc., Z is halogen atom, nitro, C 1 -C 4 alkoxy, etc., D-1 to D-60 are 5- or 6-membered aromatic heterocyclic rings, E-1 to E-49 are 5- or 6-membered saturated heterocyclic rings, m is an integer of 0 to 5, n is an integer of 0 to 4, p1 is an integer of 1 to 5. The pesticide containing these compounds.

  一种公式（1）的异氧杂环取代苯甲酰胺化合物或其盐： 其中，A1，A2和A3独立地是碳原子或氮原子，G是苯环等，X是卤素原子，C1-C6卤代烷基等，Y是卤素原子，C1-C6烷基等，R1是任意取代R16的C1-C12烷基，任意取代R16的C3-C12烯基，是氧原子或硫原子，-N（R20）R19等，R2是氢原子，C1-C4烷氧基C1-C6烷基等，R3是C1-C6卤代烷基等，R16是卤素原子，氰基，苯基，其上取代有（Z）p1，D-1至D-60，E-1至E-49等，R19是苯基，其上取代有（Z）p1等，R20是氢原子，C1-C6烷基等，Z是卤素原子，硝基，C1-C4烷氧基等，D-1至D-60是5-或6-成员芳香杂环，E-1至E-49是5-或6-成员饱和杂环，m是0至5的整数，n是0至4的整数，p1是1至5的整数。含有这些化合物的杀虫剂。
• MORPHOLINO PYRIMIDINE DERIVATIVES USED IN DISEASES LINKED TO MTOR KINASE AND/OR PI3K
  申请人：Pike Kurt Gordon

  公开号：US20100249131A1

  公开（公告）日：2010-09-30

  A compound of formula (I) or a pharamaceutically acceptable salt thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, for example in the treatment of proliferative disease such as cancer and particularly in disease mediated by an mTOR kinase and/or one or more PI3K enzyme.

  式(I)的化合物或其药学上可接受的盐，其制备过程，包含它们的制药组合物以及它们在治疗中的应用，例如在治疗增殖性疾病如癌症，特别是由mTOR激酶和/或一个或多个PI3K酶介导的疾病中的应用。
• ISOXAZOLINE-SUBSTITUTED BENZAMIDE COMPOUND AND NOXIOUS ORGANISM CONTROL AGENT
  申请人：Nissan Chemical Industries, Ltd.

  公开号：EP1731512B9

  公开（公告）日：2017-03-01